Clinical Trial

Intratumoral MMR Vaccine Injection in Borderline Resectable/Unresectable Pancreatic Cancer

Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
By doing this study, it is the hope to learn whether an injection of the measles, mumps, rubella (MMR) vaccine developed by Merck \& Co. (Merck's M-M-R® II) into the tumor is safe and effective in making the tumor smaller.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2028-03 -> 2028-08 2026-06-11
minor Completion pushed: 2028-03 -> 2028-08 2026-06-11
Trial Details
NCT Number NCT07539155
Lead Sponsor University of Arkansas
Conditions Borderline Resectable/Unresectable Pancreatic Cancer, Non Metastatic Pancreatic Cancer
Enrollment 20 participants
Start Date 2026-08
Primary Completion 2028-08 (estimated)
Study Completion 2028-08 (estimated)
Updated on ClinicalTrials.gov 2026-06-10